Hainan Shuangcheng Pharmaceuticals (002693.SZ) obtains the registration certificate for "Oxytocin Acetate Injection" drug.

Hainan Shuangcheng Pharmaceuticals (002693.SZ) announced that the company recently received the "Drug Registration Certificate" for the injection of octreotide acetate issued and approved by the National Medical Products Administration. It is reported that the injection of octreotide acetate is used to control symptoms in patients with acromegaly who cannot be adequately controlled by surgical or radiation therapy, and to reduce the plasma levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in patients. It is used to treat acromegaly patients who cannot or are unwilling to undergo surgery, or patients with acromegaly in the interval period where radiation therapy has not yet been effective; alleviate symptoms related to functional gastroenteropancreatic (GEP) neuroendocrine tumors; prevent complications after pancreatic surgery; emergency treatment for bleeding caused by gastric-esophageal varices in patients with liver cirrhosis, hemostasis, and prevention of rebleeding, used in combination with endoscopic sclerosants and other special treatments.